RESEARCH PAPER

Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity

A Crespillo^{1*}, M Alonso^{1*}, M Vida^{1*}, FJ Pavón¹, A Serrano¹, P Rivera¹, Y Romero-Zerbo¹, P Fernández-Llebrez², A Martínez³, V Pérez-Valero⁴, FJ Bermúdez-Silva^{1,5,6}, J Suárez^{1,5} and FR de Fonseca^{1,5}

¹Laboratorio de Medicina Regenerativa, Hospital Carlos Haya, Fundación IMABIS, Pabellón de Gobierno, Málaga, Spain, ²Departamento de Biología Celular, Genética y Fisiología, Facultad de Ciencias, Universidad de Málaga, Málaga, Spain, ³Institute of Medical Chemistry, the Spanish National Research Council (CSIC), Madrid, Spain, ⁴Laboratorio de Bioquímica, Hospital Carlos Haya, Málaga, Spain, ⁵CIBER OBN, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Madrid, Spain, and ⁶Neurocentre Magendie, Bordeaux, France

Correspondence

Fernando Rodríguez de Fonseca and Juan Suárez, Laboratorio de Medicina Regenerativa. Hospital Carlos Haya. Fundación IMABIS. Avenida Carlos Haya 82, 29010 Málaga, Spain. E-mail: fernando.rodriguez@fundacionimabis.org; juan.suarez@fundacionimabis.org

*These authors contributed equally to the present study.

Keywords

daidzein; diet-induced obesity; oxidative metabolism; SCD1; UCP1; PPAR; cannabinoid receptor; skeletal muscle; liver; adipose tissue

Received

21 December 2010

Revised

24 April 2011

Accepted

1 May 2011

BACKGROUND AND PURPOSE

The lack of safe and effective treatments for obesity has increased interest in natural products that may serve as alternative therapies. From this perspective, we have analysed the effects of daidzein, one of the main soy isoflavones, on diet-induced obesity in rats.

EXPERIMENTAL APPROACH

Rats made obese after exposure to a very (60%) high fat-content diet were treated with daidzein (50 mg·kg⁻¹) for 14 days. The dose was selected on the basis of the acute effects of this isoflavone on a feeding test. After 14 days, animals were killed and plasma, white and brown adipose tissue, muscle and liver studied for the levels and expression of metabolites, proteins and genes relevant to lipid metabolism.

KEY RESULTS

A single treatment (acute) with daidzein dose-dependently reduced food intake. Chronic treatment (daily for 14 days) reduced weight gain and fat content in liver, accompanied by high leptin and low adiponectin levels in plasma. While skeletal muscle was weakly affected by treatment, both adipose tissue and liver displayed marked changes after treatment with daidzein, affecting transcription factors and lipogenic enzymes, particularly stearoyl coenzyme A desaturase 1, a pivotal enzyme in obesity. Expression of uncoupling protein 1, an important enzyme for thermogenesis, was increased in brown adipose tissue after daidzein treatment.

CONCLUSIONS AND IMPLICATIONS

These results support the use of isoflavones in diet-induced obesity, especially when hepatic steatosis is present and open a new field of use for these natural products.

Abbreviations

ACC, acyl-CoA carboxylase; ACOX, acyl-CoA oxidase; AdipoR1/AdipoR2, adiponectin receptor 1 and 2; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FAS, fatty acid synthase; GGT, γ -glutamyltranspeptidase; HDL, high-density lipoprotein; HFD, high-fat diet; LDL, low-density lipoprotein; Rpl19, ribosomal protein 19; SCD1, stearoyl-CoA desaturase 1; Sp1, Sp1 transcription factor; STD, standard/low-fat diet

Introduction

Epidemiologically, the prevalence of obesity and related diseases in Asian populations is lower than in Western countries. Such observations encouraged analysis of Asian diets, which typically include soy products rich in phytoestrogens (Severson *et al.*, 1989; Tham *et al.*, 1998). Recent research has been focused on the beneficial effects of dietary phyto-oestrogens, including the oestradiol (E₂)-like soy isoflavones genistein, daidzein and glycitein, on obesity and diabetes (Kuiper *et al.*, 1998; Bhatena and Velasquez, 2002). Data obtained from clinical, epidemiological and nutritional studies in animals and humans show that the improved metabolic consequences associated with ingestion of soy products include better glucose control, less insulin resistance and improved plasma lipid profile (reducing serum total cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides) (Zhuo *et al.*, 2004; Zhan and Ho, 2005; Taku *et al.*, 2007), as well as reduction of weight gain in rats (Davis *et al.*, 2007). Such changes are protective in disorders like hyperlipidaemia, cardiovascular disease, menopausal symptoms, atherosclerosis, osteoporosis, cancer and various forms of chronic renal disease (Kopelman, 2000; Clarkson, 2002; Messina *et al.*, 2002; Clair and Anthony, 2005; Cassidy and Hooper, 2006; Zhang *et al.*, 2010), all of which are associated with obesity and diabetes.

Currently, a variety of mechanisms have been proposed through which isoflavones may exert their beneficial effects. Firstly, because of their structural similarities to endogenous oestrogens, genistein and daidzein can act as weak oestrogens after binding to and activating the oestrogen receptors, ER- α and ER- β (Kuiper *et al.*, 1998), mimicking the effects of low levels of the endogenous agonist (Zhu *et al.*, 2006). Oestradiol, among other functions, is a major regulator of adipocyte development and number and these cells are very important in lipid homeostasis and the maintenance of the whole body energy balance (Cooke and Naaz, 2004; Rosen, 2005). Oestradiol is also a well-known modulator of glucose homeostasis (Godsland, 2005) and it has also been suggested to protect beta-cell biology, modulating insulin sensitivity and biosynthesis (Le May *et al.*, 2006; Liu and Mauvais-Jarvis, 2010). Furthermore, ERs are expressed in many tissues, including adipose tissue and muscle, in a variable distribution pattern which explains their tissue-selective effects (Barros *et al.*, 2006). Secondly, soy isoflavones also produce non-oestrogen effects as genistein and daidzein bind to and activate two peroxisome proliferator-activated receptors, PPAR α and PPAR γ , increasing β -oxidation, insulin sensation and improving serum triglyceride levels (Mezei *et al.*, 2003; Shen *et al.*, 2006; Ronis *et al.*, 2009). Both PPARs have different but overlapping, tissue distribution and functions, associated with lipid and glucose metabolism (Mezei *et al.*, 2006). Therefore, isoflavones may also act through pathways regulated by PPAR-regulated genes, and/or by other transcription factors such as the sterol regulatory element binding protein (Mullen *et al.*, 2004; Ronis *et al.*, 2009). This transcription factor (sterol regulatory element binding protein) is extensively involved in glucose utilization and fatty acid synthesis and metabolism in the liver, through the control of specific genes (Shin *et al.*, 2007). Additionally, phytoestrogens are known to have potent antioxidative activity and counteract the damaging effects of free radicals in tissues (Vedavanam *et al.*, 1999).

Apart from being structurally similar to oestradiol, daidzein also resembles the natural cannabinoids (see Figure S1), the lipid compounds present in *Cannabis sativa*. The structural relationships between daidzein and plant cannabinoids may facilitate a possible cannabinoid-like effect of isoflavones yet to be described. Cannabinoids act through cannabinoid receptors, which are part of the endogenous signalling system, called the endocannabinoid system. This system is critically involved in the onset of obesity and the metabolic syndrome, mainly due to its effects on appetite control and energy homeostasis. Basically, the endocannabinoid system is a network of fatty acid-derived signalling molecules including the endocannabinoid ligands, anandamide, oleylethanolamide and 2-arachidonoyl glycerol, all of which exert their effect by binding mainly to the cannabinoid CB₁ receptors and also to CB₂ receptors (receptor nomenclature follows Alexander *et al.*, 2009). These endocannabinoids also bind to and activate PPAR α and PPAR γ (Piomelli, 2003). Furthermore, this molecular interaction is highly affected by the nature of dietary fat (Bathena, 2000; Evans *et al.*, 2004). The major metabolic organs are also the main site of action for PPARs and a variety of other hormones that could contribute to the reduction in hepatic steatosis and insulin sensitization seen after soy feeding (Cederroth and Nef, 2009).

To date, there are few studies of the effects of isoflavones on diet-induced obesity and especially of the effects caused in the main metabolic organs. To answer the questions raised, we have studied the changes caused by both diet and treatment with the isoflavone daidzein on lipid and glucose metabolism, in the three major metabolic organs: liver, adipose tissue and skeletal muscle, in order to understand the mechanism of action of isoflavones in improving metabolic parameters. Consequently, in this work, we have assessed the effect of daidzein treatment on food intake and body weight reduction in male Wistar rats and investigated the effect of a very high-fat diet (HFD) on genes relevant to lipid and glucose metabolism and related proteins, in liver, white and brown adipose tissues and skeletal muscle. We have also analysed the changes caused by treatment with daidzein on the levels of expression of these genes and proteins in rats being fed a standard/low-fat diet (STD, 10% fat) and an HFD (60% fat). Finally, we have compared the metabolic changes following the combination of the HFD and daidzein.

Because of the lack of information on cannabinoid-like actions of isoflavones, we have included in the present study the analysis of the effects of daidzein on the expression of cannabinoid receptors. From our work, we concluded that daidzein treatment may modulate the influence of the HFD on genes and proteins related to lipid and glucose metabolism, through various interrelated pathways. The most striking effects were inhibition of lipogenesis via stearoyl-CoA desaturase 1 (SCD1) and PPAR α / γ , and over activation of thermogenesis via the uncoupling protein 1 (UCP1).

Methods

Animals

All animal care and experimental procedures were performed in compliance with the European Communities directive

86/609/ECC and Spanish legislation (BOE 252/ 34367-91, 2005) regulating animal research. Male Wistar rats (~250 g, 10–12 weeks old) (Charles Rivers, Barcelona, Spain) were housed in groups of two in cages maintained in standardized conditions of animal facilities (Servicio de Estabulario, Facultad de Medicina, Universidad de Málaga) at $20 \pm 2^\circ\text{C}$ room temperature, $40 \pm 5\%$ relative humidity and a 12 h light/dark cycle with dawn/dusk effect.

Diet-induced obesity. Measurement of food, caloric intake and body weight

Rats ($n = 16$ per group) were fed for 12 weeks with two different types of diets: the HFD (60% fat diet-D12492, Brogaarden, Gentofke, Denmark) and the STD (10% fat diet-D1245B) for 10 weeks in order to induce obesity. The STD consisted of $3.85 \text{ kcal}\cdot\text{g}^{-1}$ (with 20% protein, 70% carbohydrates and 10% fat) and the HFD had $5.24 \text{ kcal}\cdot\text{g}^{-1}$ (of which, 20% of the metabolizable energy content was protein, 20% carbohydrates and 60% fat) (see Table S1). The accumulated food/caloric intake by each rat and their body weight gain were measured every day for 12 weeks. Treatment with daidzein was started when the weight curves showed a clear divergence and stabilization between the two diets was reached, which lasted 10 weeks (see Figure S2).

Treatment

After 10 weeks (divergence of weight curves), diet-fed rats received one injection (i.p.) or a daily i.p. injection of either vehicle ($1 \text{ mL}\cdot\text{kg}^{-1}$ of 10% Tocrisolve in saline) or daidzein (7- β -glucoside; LC Laboratories, Woburn, WA, USA) at 5 or $50 \text{ mg}\cdot\text{kg}^{-1}$, dissolved in 10% Tocrisolve for acute dose-response treatment, and at $50 \text{ mg}\cdot\text{kg}^{-1}$ for subchronic treatment during 14 days, while the diets remained unchanged (Figure S2). After one administration of daidzein (acute treatment), the accumulated food intake was measured over a time course of 30, 60, 120 and 240 min. During subchronic treatment, we measured the accumulated food/caloric intake and the body weight gain every day during the 14 days of treatment (see Figure S2). Finally, we generated six experimental groups for acute treatment with daidzein: STD-Vehicle, STD-Daidzein $5 \text{ mg}\cdot\text{kg}^{-1}$, STD-Daidzein $50 \text{ mg}\cdot\text{kg}^{-1}$, HFD-Vehicle, HFD-Daidzein $5 \text{ mg}\cdot\text{kg}^{-1}$ and HFD-Daidzein $50 \text{ mg}\cdot\text{kg}^{-1}$; and four experimental groups for subchronic treatment with daidzein: STD-Vehicle, STD-Daidzein, HFD-vehicle and HFD-Daidzein.

Sample collection

Animals from the four experimental groups were anaesthetized (sodium pentobarbital, $50 \text{ mg}\cdot\text{kg}^{-1}$, i.p.) 2 h after the last dose of treatment in a room separate from the other experimental animals. Blood samples were briefly collected from the orbital cavity and centrifuged ($1250\times g$ for 8 min, 4°C), and all plasma samples were frozen at -80°C for biochemical and hormonal analysis. Liver, white and brown adipose tissues and skeletal muscle from the abdominal wall were dissected. Part of each sample was fixed with 4% paraformaldehyde in 0.1 M PBS by immersion until immunohistochemical analysis. The remaining of each sample,

excluding brown adipose tissue, was frozen at -80°C until RT-PCR analysis.

RNA isolation and RT-PCR analysis

RNA from liver, skeletal muscle and adipose tissue samples was extracted using Trizol® method, according to the manufacturer's instructions (Gibco BRL Life Technologies, Baltimore, MD, USA). Samples of liver, skeletal muscle and adipose tissue (~100, ~100 and ~300 mg respectively) were placed into 1–3 mL of Trizol Reagent (Invitrogen, CA, USA) and homogenized with an IKA-Ultra-Turrax® T8 (IKA-Werke GmbH, Staufen, Germany). In order to ensure purity of the mRNA sequences excluding molecules smaller than 200 nucleotides, RNA samples were isolated with RNeasy minelute cleanup kit (Qiagen, Hilden, Germany), which included digestion with DNase I column (Rnase-free DNase Set, Qiagen), according to manufacturer's instructions. Total mRNA concentration was quantified using a spectrophotometer (Eppendorf® BioPhotometer, Hamburg, Germany) to ensure A260/280 ratios of 1.8 to 2.0.

Reverse transcriptase reactions were carried out with $4 \mu\text{g}$ of muscle mRNA or liver mRNA and $1 \mu\text{g}$ of adipose tissue mRNA using the Transcriptor Reverse Transcriptase kit and random hexamer primers (Transcriptor RT, Roche Diagnostic GmbH, Mannheim, Germany). Negative controls included reverse transcription reactions omitting reverse transcriptase. Quantitative real-time reverse transcription PCR (quantitative RT-PCR) was performed using an iCycler System (Bio-Rad, Hercules, CA, USA) or a CFX96™ Real-Time PCR Detection System (Bio-Rad), and the SYBR Green detection format (FastStart Universal Master Kit, Roche, Mannheim, Germany). Sample quantification was carried out differently in the three tissues for better performance. Skeletal muscle and liver samples were analysed by the classic standard curve method, whereas adipose tissue samples were analysed by relative quantification following In-Silico PCR system technology. Each reaction was run in duplicate and contained $5 \mu\text{L}$ of cDNA. For muscle and liver samples, cycling parameters were: 95°C for 3 min and 30 s to activate DNA polymerase followed by 45 cycles at 95°C for 15 s, annealing temperature for 30 s and a final extension step of 72°C for 15 s in which fluorescence was acquired. Melting curves analysis were performed to ensure only a single product was amplified. We analysed various housekeeping genes, selecting the most suitable for each tissue according to their homogeneity. Absolute values from each sample were normalized with regard to the housekeeping gene for β -actin, in skeletal muscle and for Sp1 in liver. For adipose tissue samples, cycling parameters were: 95°C for 5 min and 30 s to activate DNA polymerase followed by 40 cycles at 95°C for 10 s, annealing temperature for 30 s at 60°C and a final extension step of 72°C for 15 s in which fluorescence was acquired. The accepted amplification limit of the non-template controls was selected five cycles below the samples C_p value. The mean PCR amplification efficiency and quantification cycle for each gene was calculated by submitting raw fluorescence data generated with the CFX96 software (Bio-Rad) to Real-Time PCR Miner software (<http://www.miner.ewindup.info>). The qBase Excel software program was used to measure the relative expression level for each gene, and geNorm application for selecting reference genes to normalize mRNA expres-

sion levels, determining that Sp1 and Rpl19 were stable for this treatment. Finally, Sp1 was the reference gene selected to normalized mRNA expression levels in adipose tissue. Primers for PCR reaction (Table S2) were designed based on NCBI database sequences of rat reference mRNA, checked for specificity with BLAST software from NCBI website (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) and synthesized by Invitrogen.

Oil Red O staining

Liver samples were analysed for lipid and fat depots by staining with a fat-specific dye, Oil Red O. Frozen samples were cut into 30 μ m-thick sections using a sliding microtome (Leica SM200R, Wetzlar, Germany) and fixated with 10% formal calcium. Sections were washed with distilled water and rinsed with 60% isopropanol. Then, sections were stained with freshly prepared Oil Red O working solution for 20 min (Oil Red O stock stain: 0.5 g of Oil Red O and 100 mL of isopropanol; Oil Red O working solution: 30 mL of the stock stain and 20 mL of distilled water). Sections were rinsed with 60% isopropanol, lightly stained with Mayer's haematoxylin, rinsed with tap water and mounted in aqueous mountant.

Immunohistochemistry

Paraffined tissue microarray blocks (Manual Tissue Arrayer MTA-1, beecher Instruments, Inc., Sun Prairie, WI, USA) of rat liver and brown adipose tissue were analysed for the presence and quantification of PPAR α , SCD1, fatty acid synthase (FAS) and UCP1 by immunohistochemistry, immunofluorescence and quantified by densitometry. The primary antibodies were: rabbit polyclonal antibody PPAR α (diluted 1:200; ABR cat. n° PA1-822A, Golden, CO, USA), goat polyclonal antibody SCD1 (diluted 1:50; Santa Cruz cat. n° sc-14720, Santa Cruz, CA, USA), rabbit polyclonal antibody FAS (diluted 1:50; Cell Signaling cat. #3180) and goat polyclonal antibody UCP1 (diluted 1:50; Santa Cruz cat. n° sc-14720) (see Appendix S1).

Digital high-resolution microphotographs of the liver and brown adipose tissue were taken under the same conditions of light and brightness/contrast by an Olympus BX41 microscope equipped with a 10x objective, an Olympus DP70 digital camera (Olympus Europa GmbH, Hamburg, Germany) and an Olympus X-Cite fluorescence system (X-Cite series 120Q, Olympus). Quantification of immunoreactivity and immunofluorescence were carried out by measuring densitometry of the images obtained from replicates and samples: two replicates per sample, eight samples per group and four groups, using the analysis software ImageJ 1.38x (National Institute of Health, Bethesda, MD, USA).

Data analysis

All data are shown as mean $\pm$ SEM of at least eight determinations per experimental group. Kolmogorov–Smirnov normality tests indicated that all data followed a Gaussian distribution ($P > 0.1$), so we selected a parametric statistical test. Differences between the diets and treatments were analysed by two-way ANOVA for repeated measures, followed by Bonferroni *post hoc* test for multiple comparisons. The level of statistical significance was set at $P < 0.05$.

Results

In order to control the effect of the HFD and daidzein treatment; we first monitored the accumulated food/caloric intake and body weight gain after either acute (dose-response) or subchronic treatment. We have also analysed biochemical parameters such as glucose, triglycerides, cholesterol and hepatic enzymes, among others, and plasma levels of adiponectin, insulin and leptin. In order to analyse the metabolic impact of an HFD (60% fat) and the response to daidzein treatment we studied the expression of specific genes and proteins in the liver, white and brown adipose tissues and skeletal muscle. The selected enzymes and receptors represent a selection of molecules implicated in lipid and glucidic metabolism with a putative role in energy metabolism. Clearly, the physiological differences between liver, skeletal muscle and adipose tissues determine that the molecules analysed for gene expression are not the same in the three tissues. So, the nuclear receptors PPAR α and PPAR γ and the acetyl-CoA-oxidase (ACOX) were analysed in these three tissues. The hormones adiponectin and leptin were analysed in the white adipose tissue only as well as its receptors, the adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2) in the skeletal muscle and liver respectively. Additional gene expressions for FAS and SCD1 were analysed in liver and white adipose tissue; the growth hormone receptor in muscle and liver; acyl-CoA carboxylase (ACC) only in adipose tissue and fatty acid binding protein 1 only in liver. The results obtained for gene expressions were compared with those for the corresponding proteins, for PPAR α , SCD1 and FAS in liver. In addition, UCP1, an enzyme involved in the regulation of body temperature and glucose metabolism, was analysed in brown adipose tissue. SCD1 has recently been shown to be a critical control point of lipid partitioning and body weight regulation. It catalyses the rate-limiting step in the biosynthesis of monounsaturated fatty acids, which are required for normal rates of synthesis of triglycerides, cholesterol esters and phospholipids (Dobrzyn *et al.*, 2004). Finally, we also evaluated the gene expression of the cannabinoid CB₁ and CB₂ receptors in the three tissues.

Effect of diet on accumulated food, caloric intake and body weight gain

The accumulated food intake, caloric intake and body weight gain in the rats fed with either the STD (10% fat) or with the HFD (60% fat) over the first 10 weeks of the feeding period are shown in Figure S3. Rats fed with STD accumulated significantly more food intake than rats fed with the HFD from the day 15 on ($P < 0.01$ between day 14 and 16, $P < 0.001$ from day 17 on) (Figure S3A). On the contrary, the accumulated caloric intake was higher in HFD than in STD rats and such differences were also statistically significant from the day 30 on ($P < 0.05$ in day 30, $P < 0.01$ between day 34 and 41, $P < 0.001$ from day 42 on) (Figure S3B). The lower food intake in HFD rats is due to the higher caloric/energy content in the HFD than the STD (Table S1). Accumulated caloric intake correlates with the body weight increase (Figure S3C). Interestingly, body weight gain also showed a significant divergence in HFD

Figure 1

Dose–response effects of acute administration of daidzein at 5 and 50 mg·kg⁻¹ on accumulated food intake in male rats fed with a standard/low-fat diet (STD) and a very high-fat diet (HFD) at different periods of time 30, 60, 120 and 240 min. There was a significant reduction in accumulated food intake using the 50 mg·kg⁻¹ dose of daidzein in both STD (A) and HFD (B) in all the time periods analysed in the experiment. On the contrary, the 5 mg·kg⁻¹ dose of daidzein did not exert any effects on food intake in the time periods analysed. Histograms represent the mean $\pm$ SEM (eight animals per group). Two-way ANOVA followed by Bonferroni *post test*: *** P < 0.001 significantly different from vehicle-treated STD group; ## P < 0.01 significantly different from vehicle-treated HFD group. Treatment effects are summarized in Table S3.

rats in comparison with STD rats from the eighth week on (56 days) (P < 0.05 in day 56, P < 0.01 from day 57 on). Two-way ANOVA analysis showed a very significant diet effect on accumulated food intake [Diet: $F(1,900) = 3092.56$, P < 0.0001], accumulated caloric intake [Diet: $F(1,900) = 447.53$, P < 0.0001] and body weight gain [Diet: $F(1,900) = 130.75$, P < 0.0001]. When body weight gain was stable over time (after 10 weeks in each of the diets), we scheduled both acute (5 and 50 mg·kg⁻¹) and subchronic (50 mg·kg⁻¹) treatments with daidzein, while the diets remained unchanged.

Dose–response of the accumulated food intake with STD and HFD after acute treatment with daidzein

After a feeding period of 10 weeks, rats only received one injection (acute treatment) of either vehicle or two different doses of daidzein (5 mg·kg⁻¹ and 50 mg·kg⁻¹), at different periods of time 30, 60, 120 and 240 min (Figure 1). This was to identify the optimal dose at which treatment with daidzein would be more effective on food/caloric intake and body weight changes. We detected a marked reduction in accumu-

Figure 2

Effects of the STD and the HFD for 10 days before daidzein administration and during 14 days of daidzein treatment ($50 \text{ mg}\cdot\text{kg}^{-1}$) on accumulated food/caloric intake and body weight gain, while the diets remained unchanged. Treatment with daidzein reduced accumulated food (A) and caloric (B) intake in both diets, from day 8 of treatment, and this correlated with a significant body weight decrease (C). Arrows point to the beginning of daidzein administration. Histograms represent the mean $\pm$ SEM (eight animals per treated group). Two-way ANOVA followed by Bonferroni *post hoc* test: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ significantly different from daidzein-treated HFD group; # $P < 0.05$, ## $P < 0.01$, ### $P < 0.001$ significantly different from daidzein-treated STD group. Treatment effects are summarized in Table S3.

lated food intake using the $50 \text{ mg}\cdot\text{kg}^{-1}$ dose of daidzein in both STD ($P < 0.001$) and HFD ($P < 0.01$) in all the time periods analysed in the experiment (Figure 1A and B). On the contrary, the $5 \text{ mg}\cdot\text{kg}^{-1}$ dose of daidzein did not affect food intake in the time periods analysed. Interestingly, two-way ANOVA analysis showed that daidzein induced a significant decrease by a dose-response effect on accumulated food intake in STD [$5 \text{ mg}\cdot\text{kg}^{-1}$: $F(1,56) = 5.51$, $P < 0.05$; $50 \text{ mg}\cdot\text{kg}^{-1}$: $F(1,56) = 479.4$, $P < 0.0001$], while daidzein produced an opposite dose-response on accumulated food intake in HFD [raised at $5 \text{ mg}\cdot\text{kg}^{-1}$: $F(1,56) = 11.98$, $P = 0.001$; decreased at $50 \text{ mg}\cdot\text{kg}^{-1}$: $F(1,56) = 122.15$, $P < 0.0001$]. These results indicated that the $50 \text{ mg}\cdot\text{kg}^{-1}$ dose of daidzein was the most appropriate for the subchronic experiment.

Effect of subchronic treatment with daidzein on accumulated food/caloric intake and body weight gain

After a feeding period of 10 weeks, rats received a daily dose of either vehicle ($1 \text{ mL}\cdot\text{kg}^{-1}$ of 10% Tocrisolve) or daidzein ($1 \text{ mL}\cdot\text{kg}^{-1}$ of $50 \text{ mg}\cdot\text{kg}^{-1}$ in 10% Tocrisolve) during 14 days, while the diets remained unchanged (Figure 2). Treatment with daidzein reduced the accumulated food intake in rats on both diets from the day 11 of treatment on (Figure 2A), while daidzein reduced accumulated caloric intake only in rats on STD from the day 6 of treatment until the end of the experiment (Figure 2B). This also correlated with a decrease in body weight gain in both diets from days 3–4 of treatment, an effect more prominent in HFD feeding (Figure 2C). Two-way ANOVA analysis showed that daidzein induced a significant decrease on accumulated food intake [Treatment: $F(1,196) = 48.27$, $P < 0.0001$ for STD; $F(1,196) = 76.69$, $P < 0.0001$ for HFD], accumulated caloric intake [Treatment: $F(1,196) = 133.89$, $P < 0.0001$ for STD; $F(1,196) = 34.33$, $P < 0.0001$ for HFD] and average body weight gain [Treatment: $F(1,196) = 92.08$, $P < 0.0001$ for STD; $F(1,196) = 130.36$, $P < 0.0001$ for HFD].

Fat profile in skeletal muscle and liver after diet and subchronic treatment of daidzein

To assess the magnitude of the changes in accumulated fat deposits on the metabolic tissues studied in our models; we analysed the total fat content in both skeletal muscle and liver (Figure 3). In skeletal muscle, daidzein treatment did not

affect fat content [Treatment: $F(1,26) = 3.917$, $P = 0.058$] (Figure 3A). In liver, after HFD, there was a significant increase in the amount of fat [Diet: $F(1,25) = 9.27$, $P < 0.01$] (Figure 3B). We did not detect interaction between diet and treatment factors in any case.

The biochemical analysis of fat content agreed with the results obtained with a specific lipid and fat depot stain, Oil Red O, in liver (Figure 4). The fat depots in the liver of rats fed with the HFD were increased ($P < 0.01$; Figure 4A–C) and were decreased after daidzein treatment ($P < 0.05$; Figure 4A, C and E). Two-way ANOVA analysis also revealed a significant effect

Figure 3

Effects of a subchronic treatment of daidzein ($50 \text{ mg} \cdot \text{kg}^{-1}$, 14 days) on skeletal muscle and liver fat profile in male rats fed with the STD or the HFD. There were no significant differences in the amount of fat in the skeletal muscle with either diet or daidzein treatment (A). There was only a significant increase in the amount of fat in the liver by a diet effect (B). Histograms represent the mean $\pm$ SEM (eight animals per group). Two-way ANOVA followed by Bonferroni *post hoc* test: $**P < 0.05$ for diet effect.

between diets [Diet: $F(1,8) = 11.45$, $P < 0.01$]. We also detected a significant interaction between both factors [diet vs. treatment: $F(1,8) = 14.49$, $P < 0.01$], that is, daidzein induced a different effect on liver fat content depending on the diet. Interestingly, it seems that treatment with daidzein reverses the amount of fat in the liver caused by high-fat feeding (Figures 3B and 4A).

Effect of diet and subchronic treatment with daidzein on plasma metabolites and liver enzymes

Results of the analysis of plasma metabolites and liver enzymes analysed are shown in Table 1. The HFD showed a significant decrease in the circulating levels of urea ($P < 0.05$) and triglycerides ($P < 0.01$), compared with values in the STD group. Some of these results could be explained by the composition of the two diets used (Table S1). Combining STD and treatment with daidzein ($50 \text{ mg} \cdot \text{kg}^{-1}$) decreased the plasma levels of creatinine ($P < 0.001$), urea, high-density lipoprotein

Figure 4

Effect of a subchronic treatment of daidzein ($50 \text{ mg} \cdot \text{kg}^{-1}$, 14 days) on liver fat depots in male rats fed with the STD or the HFD. We found a significant increase in the fat depots in the liver after HFD feeding; and a significant fall after daidzein treatment in HFD-fed rats (A). Representative high-magnification images from the liver, stained with Oil Red O in the four rat groups (B–E). Histograms represent the mean $\pm$ SEM (three animals per group). Two-way ANOVA followed by Bonferroni *post hoc* test: $**P < 0.01$ significantly different from vehicle-treated STD group, $^{\$}P < 0.05$ significantly different from vehicle-treated HFD group, $^{\$}P < 0.01$ for diet effect. Scale bar is shown in image B.

(HDL)-cholesterol and triglycerides ($P < 0.05$), compared with those in vehicle-treated animals (Table 1). However, glucose levels were very significantly increased after treatment with daidzein ($P < 0.01$). The combination of HFD with daidzein

Table 1

Effect of diet and daidzein on plasma metabolites of obese male Wistar rats

Plasma metabolites	STD Vehicle	Daidzein	HFD Vehicle	Daidzein
Glucose (mg·mL ⁻¹)	1.052 ± 0.089	1.638 ± 0.121**	0.75 ± 0.109	1.205 ± 0.133 [#]
Urea (mg·mL ⁻¹)	0.395 ± 0.017	0.326 ± 0.024*	0.338 ± 0.0074*	0.267 ± 0.0187
Creatinine (mg·mL ⁻¹)	0.0082 ± 0.0002	0.0058 ± 0.0002***	0.0086 ± 0.0002	0.0065 ± 0.0004###
Uric acid (mg·mL ⁻¹)	0.0057 ± 0.0017	0.0066 ± 0.0007	0.0043 ± 0.0007	0.0060 ± 0.0011
HDL-C (mg·mL ⁻¹)	0.273 ± 0.012	0.223 ± 0.012*	0.227 ± 0.015	0.245 ± 0.016
Triglycerides (mg·mL ⁻¹)	2.007 ± 0.331	1.133 ± 0.113*	0.935 ± 0.148**	0.914 ± 0.180
Cholesterol (mg·mL ⁻¹)	0.920 ± 0.073	0.716 ± 0.051	0.816 ± 0.087	0.761 ± 0.051
ALT (U·L ⁻¹)	41.12 ± 3.88	36.63 ± 6.65	48.12 ± 4.75	37.85 ± 2.53
AST (U·L ⁻¹)	112.57 ± 14.04	77.13 ± 6.41	112.38 ± 20.60	95.43 ± 30.34
GGT (U·L ⁻¹)	6.12 ± 0.74	5.75 ± 0.56	5.86 ± 0.43	5.53 ± 0.67

Data shown are the plasma levels of metabolites in rats fed with STD or HFD and treated with vehicle or daidzein (50 mg·kg⁻¹, 14 days). Values represent the mean ± SEM (eight animals per treated group). Two-way ANOVA and Bonferroni *post test* for multiple comparisons: **P* < 0.05, ***P* < 0.01, ****P* < 0.001 significantly different from STD rats treated with vehicle; [#]*P* < 0.05, ###*P* < 0.001 significantly different from HFD rats treated with vehicle. Diet, treatment and interaction effects are summarized in Table S3.

decreased levels of creatinine in plasma (*P* < 0.001). Once again, glucose levels were raised after HFD and treatment with daidzein, although less than the results with STD (Table 1). Two-way ANOVA analysis revealed a significant diet effect in the plasma levels of glucose [Diet: *F*(1,27) = 10.49, *P* < 0.01], urea [Diet: *F*(1,27) = 10.68, *P* < 0.01], creatinine [Diet: *F*(1,27) = 4.69, *P* < 0.05] and triglycerides [Diet: *F*(1,27) = 9.2, *P* < 0.01] and a significant treatment effect in the plasma levels of glucose [Treatment: *F*(1,27) = 21.04, *P* < 0.0001], urea [Treatment: *F*(1,27) = 9.87, *P* < 0.01], creatinine [Treatment: *F*(1,27) = 76.56, *P* < 0.0001], triglycerides [Treatment: *F*(1,27) = 4.41, *P* < 0.05] and cholesterol [Treatment: *F*(1,27) = 3.53, *P* < 0.05]. We only detected interaction in HDL-cholesterol [Diet vs. Treatment: *F*(1,26) = 5.89, *P* < 0.05], that is, daidzein had a different effect on HDL-cholesterol depending on the diet.

Although plasma levels of transaminases (ALT, AST and GGT) did not differ between diets or treatment of the four experimental groups, there was a tendency towards decreased AST, after treatment with daidzein with either STD or HFD (Table 1). We did not detect interaction between diet and treatment in any case. Table S3 summarizes the significance and the direction of the diet and treatment effects, including the interaction between both factors, on plasma metabolites.

Effect of diet and subchronic treatment with daidzein on plasma hormone levels

Treatment with daidzein (50 mg·kg⁻¹) did not affect insulin in plasma using either diet (Figure 5A). However, the levels of adiponectin in plasma were reduced after treatment with daidzein in both STD and HFD groups (both at *P* < 0.05) (Figure 5B). Two-way ANOVA analysis confirmed a significant decrease on adiponectin levels by daidzein [Treatment, *F*(1,27) = 14.11, *P* < 0.001]. Interestingly, daidzein induced a significant increase on leptin levels [Treatment, *F*(1,17) = 9.05, *P* < 0.01] (Figure 5C). We did not detect interaction

between diet and treatment in any case. Table S3 summarizes the significance and the direction of the diet and treatment effects, including the interaction between both factors, on plasma hormone levels.

Effect of diet on the expression of selected genes for metabolic control in white adipose tissue, skeletal muscle and liver

After the complete feeding period (12 weeks) with either the STD or the HFD, animals were killed and samples from adipose tissue, skeletal muscle and liver extracted and processed for RT-PCR analysis. As shown in Figure 6, changes in gene expression were most marked in adipose tissue and least in skeletal muscle. Table S3 summarizes the significance and the direction of the diet effects on gene expression.

White adipose tissue. Feeding with the HFD increased the levels of leptin and ACOX, and of the cannabinoid CB₁ receptor (*P* < 0.001). HFD feeding also decreased gene expression of the enzymes ACC (*P* < 0.001) and FAS (*P* < 0.05) (Figure 6A). Gene expression of any of the remaining molecules and enzymes studied in adipose tissue were not affected by the HFD. Two-way ANOVA analysis showed a diet effect on PPARα [*F*(1,20) = 5.11, *P* < 0.05], leptin [*F*(1,21) = 29.34, *P* < 0.0001], ACOX [*F*(1,22) = 23.36, *P* < 0.0001], ACC [*F*(1,22) = 19.08, *P* < 0.001], FAS [*F*(1,22) = 20.37, *P* < 0.001], CB₁ receptor [*F*(1,22) = 47.91, *P* < 0.0001] and CB₂ receptor [*F*(1,23) = 6.02, *P* < 0.05] gene expressions (Table S3).

Skeletal muscle. PPARα and CB₂ receptor gene expression was reduced (*P* < 0.01 and *P* < 0.05 respectively) after the HFD (Figure 6B). Although not significant, there was a tendency towards a decrease for the other molecules analysed in the skeletal muscle. Two-way ANOVA analysis showed a diet effect on PPARγ [*F*(1,25) = 7.22, *P* < 0.05] and CB₂ receptor [*F*(1,23) = 10.47, *P* < 0.01] gene expressions (Table S3).

Figure 5

Effects of a subchronic treatment of daidzein (50 mg·kg⁻¹, 14 days) on plasma insulin (A), adiponectin (B) and leptin (C) levels in rats fed with the STD or the HFD. Treatment with daidzein did not affect levels of insulin, but reduced levels of adiponectin and increased levels of leptin in the plasma of both STD and HFD rats. Histograms represent the mean ± SEM (eight animals per group). Two-way ANOVA followed by Bonferroni *post hoc* test: * $P < 0.05$ significantly different from vehicle-treated groups, ** $P < 0.01$ and *** $P < 0.001$ for treatment effect.

Liver. Liver is the main regulatory organ with specific metabolic effects in the other peripheral tissues. In our model, the HFD increased expression of PPAR α , PPAR γ and ACOX ($P < 0.05$, $P < 0.01$ and $P < 0.05$ respectively). However, the same

diet reduced the enzymes, SCD1 and FAS ($P < 0.001$). Such decreases in synthetic enzymes agreed with results observed in adipose tissue. No significant changes were observed for the remaining molecules analysed in liver (Figure 6C). Two-way ANOVA analysis showed a diet effect on PPAR α [$F(1,22) = 9.54$, $P < 0.01$], PPAR γ [$F(1,23) = 9.3$, $P < 0.01$], ACOX [$F(1,23) = 6$, $P < 0.05$], SCD1 [$F(1,20) = 21.09$, $P < 0.001$], FAS [$F(1,21) = 30.53$, $P < 0.0001$] and CB₂ receptor [$F(1,21) = 4.73$, $P < 0.05$] gene expressions (Table S3).

Effect of diet and subchronic treatment with daidzein on the expression of selected genes for metabolic control in white adipose tissue, skeletal muscle and liver

After feeding with STD or HFD for 10 weeks, rats received a daily i.p. injection of daidzein (50 mg·kg⁻¹) for 14 days, then were killed 2 h after treatment and samples from their adipose tissue, skeletal muscle and liver extracted and analysed by RT-PCR (Figures 7 and 8). Table S3 summarizes the significance and the direction of the treatment effect on gene expression, including the interaction between diet and treatment.

White adipose tissue. Treatment with daidzein and the STD decreased gene expression of the lipogenic enzyme ACC only ($P < 0.05$), with no effect on the rest of molecules studied in this tissue (Figure 7A). Feeding with the HFD and treatment with daidzein reduced the levels of adiponectin ($P < 0.05$), leptin ($P < 0.001$) and ACOX ($P < 0.001$) (Figure 8A). Although not significant, the levels of SCD1 also showed a tendency to decrease. However, such treatment did not have any effects on PPAR α , ACC or the CB₁ and CB₂ receptors (Figure 8A). Two-way ANOVA analysis only showed a significant treatment effect on leptin gene expression [$F(1,21) = 6.69$, $P < 0.05$], and a tendency for ACOX and SCD1 gene expressions ($P < 0.06$). Interaction between diet and treatment was detected in adiponectin [$F(1,21) = 5.98$, $P < 0.05$], leptin [$F(1,21) = 21.03$, $P < 0.001$] and ACOX [$F(1,22) = 23.36$, $P < 0.0001$] gene expressions, that is, daidzein had a different effect depending on the diet (Table S3).

Skeletal muscle. Expression of the nuclear receptors PPAR α and PPAR γ was reduced ($P < 0.01$ and $P < 0.05$ respectively) after feeding with the STD and treatment with daidzein. There were no effects on the other genes studied (Figure 7B). Feeding with the HFD and treatment with daidzein did not change the expression of any of the genes studied in skeletal muscle (Figure 8B). Two-way ANOVA analysis did not detect treatment effect on any of the genes analysed, but detected interaction between diet and treatment, that is, daidzein produced a different response depending on the diet in PPAR α [$F(1,26) = 11.87$, $P < 0.01$], PPAR γ [$F(1,25) = 9.92$, $P < 0.01$], ACOX [$F(1,26) = 5.57$, $P < 0.05$] and growth hormone receptor [$F(1,26) = 5.65$, $P < 0.05$] gene expressions (Table S3).

Liver. After treatment with daidzein using the STD, the mRNA levels of SCD1 and FAS ($P < 0.01$), both lipogenic enzymes, were reduced in liver. There were no changes on the gene expression for any of the other molecules (Figure 7C).

Figure 6

Effects of diet on gene expression of molecules involved in glucose and lipid metabolism, in adipose tissue, skeletal muscle and liver. Regarding the adipose tissue, HFD feeding increased gene expression of leptin, ACOX and CB₁ receptors, but decreased those of ACC and FAS. In the skeletal muscle, gene expression of PPAR α and CB₂ receptors was reduced after the HFD. In liver, the HFD increased gene expression for PPAR α , PPAR γ and ACOX, but reduced those of SCD1 and FAS. Values from each sample were normalized with regard to the housekeeping gene Sp1 for adipose tissue and liver and β -actin for skeletal muscle. Histograms represent the mean $\pm$ SEM (eight animals per group). Two-way ANOVA followed by Bonferroni *post hoc* test: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ significantly different from STD. Diet, treatment and interaction effects are summarized in Table S3.

Combination of daidzein and the HFD reduced the levels of PPAR γ gene expression in liver ($P < 0.05$), without affecting expression of the other genes (Figure 8C). Two-way ANOVA analysis showed a significant treatment effect on PPAR α [$F(1,22) = 6.05$, $P < 0.05$], PPAR γ [$F(1,23) = 4.32$, $P < 0.05$] and SCD1 [$F(1,20) = 6.74$, $P < 0.05$] gene expressions. Daidzein produced a different effect depending on the diet (interaction) in PPAR γ [$F(1,23) = 4.32$, $P < 0.05$], ACOX [$F(1,23) = 4.6$, $P < 0.05$], SCD1 [$F(1,20) = 6.38$, $P < 0.05$] and FAS [$F(1,21) = 12.39$, $P < 0.01$] gene expressions (Table S3).

Effect of diet and daidzein on the expression of selected proteins for metabolic control in liver and brown adipose tissue

After evaluating the most relevant changes observed on gene expression, we analysed the levels of proteins such as PPAR α , SCD1 and FAS in liver, and UCP1 in brown adipose tissue. Figure 9 shows a panel of representative high-magnification images from the liver immunostained for PPAR α , SCD1 and FAS in the four rat groups (STD, STD-daidzein, HFD, HFD-daidzein).

Figure 7

Effect of a subchronic treatment of daidzein ($50 \text{ mg} \cdot \text{kg}^{-1}$, 14 days) using the STD, on gene expression of molecules involved in glucose and lipid metabolism, in adipose tissue, skeletal muscle and liver. There was a decrease in the levels of gene expression of ACC in adipose tissue (A), PPAR α and PPAR γ in skeletal muscle (B), and SCD1 and FAS in liver (C). Values from each sample were normalized with regard to the housekeeping gene Sp1 for adipose tissue and liver and β -actin for skeletal muscle. Histograms represent the mean $\pm$ SEM (eight animals per group). Two-way ANOVA followed by Bonferroni *post hoc* test: * $P < 0.05$, ** $P < 0.01$ significantly different from vehicle. Diet, treatment and interaction effects are summarized in Table S3.

Figure 8

Effect of a subchronic treatment of daidzein ($50 \text{ mg} \cdot \text{kg}^{-1}$, 14 days) using the HFD, on gene expression of molecules involved in glucose and lipid metabolism, in adipose tissue, skeletal muscle and liver. Gene expression of adiponectin, leptin and ACOX in adipose tissue (A), and PPAR γ in liver (C) were decreased. None of the genes studied in skeletal muscle were changed. Values from each sample were normalized with regard to the housekeeping gene Sp1 for adipose tissue and liver and β -actin for skeletal muscle. Histograms represent the mean $\pm$ SEM (eight animals per group). Two-way ANOVA followed by Bonferroni *post hoc* test: * $P < 0.05$, *** $P < 0.001$ significantly different from vehicle. Diet, treatment and interaction effects are summarized in Table S3.

Figure 9

Effects of diet and daidzein treatment ($50 \text{ mg} \cdot \text{kg}^{-1}$, 14 days) on protein expression of PPAR α , SCD1 and FAS in liver by immunohistochemistry, immunofluorescence and densitometry. Representative high-magnification images from liver samples, immunostained for PPAR α (A–D), SCD1 (F–I) and FAS (K–N) in the four rat groups (STD, STD-daidzein, HFD, HFD-daidzein). Quantification of densitometry showed an increase of PPAR α expression in HFD (E), a decrease of SCD1 expression in HFD that was accentuated after daidzein treatment in both diets (J), and a decrease of FAS expression in HFD (O). Histograms represent the mean $\pm$ SEM (eight animals per group). Two-way ANOVA followed by Bonferroni *post hoc* test: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ versus vehicle-treated STD group, $^{\&}$ $P < 0.05$ significantly different from vehicle-treated HFD group, ss $P < 0.01$, sss $P < 0.001$ for diet effect, $^{\#}$ $P < 0.05$, $^{##}$ $P < 0.01$, $^{###}$ $P < 0.001$ for daidzein effect. Scale bar is shown in (A), (F) and (K). Diet, treatment and interaction effects are summarized in Table S3.

HFD-daidzein). Densitometric analysis of these images showed changes similar to those of the gene expression studies. Immunoreactive PPAR α was increased in HFD rats ($P < 0.05$; Figure 9E), but tended to decrease after daidzein treatment. Two-way ANOVA analysis also revealed a significant effect between diets [Diet, $F(1,28) = 11.24$, $P < 0.01$] and a significant effect with daidzein [Treatment, $F(1,28) = 4.22$, $P < 0.05$] (Table S3). SCD1 immunofluorescence was decreased in HFD rats ($P < 0.01$; Figure 9J), a change accentuated in rats treated with daidzein and fed with either diet ($P < 0.001$ for STD; $P < 0.05$ for HFD). Two-way ANOVA analysis also revealed a significant effect between diets [Diet, $F(1,24) = 21.45$, $P < 0.001$] and a significant effect with daidzein [Treatment, $F(1,24) = 26.36$, $P < 0.001$]. FAS also showed a very significant decrease on the immunofluorescence levels in HFD rats ($P < 0.001$). Diet effect was confirmed after two-way ANOVA analysis [Diet, $F(1,28) = 119.37$, $P < 0.0001$] (Table S3). In Figure 10, UCP1 immunofluorescence in brown adipose tissue was

increased by daidzein with either diet [Treatment, $F(1,27) = 5.65$, $P < 0.05$] (Figure 10A and Table S3).

Discussion

In many clinical trials and animal studies, feeding with soy isoflavones improved blood lipid profiles and glucose metabolism and, therefore, was beneficial for several chronic disorders associated with obesity and diabetes (Clarkson, 2002; Messina *et al.*, 2002; Clair and Anthony, 2005; Cassidy and Hooper, 2006; Zhang *et al.*, 2010). However, the hypo-lipidaemic actions of isoflavones and the mechanisms involved are still debated.

Here, we have evaluated the effects of the HFD and the responses to a subchronic treatment with daidzein, on body weight and several plasma parameters. We have also identified the molecular changes in the physiological pathways of

Figure 10

Effects of diet and daidzein treatment (50 mg·kg⁻¹, 14 days) on protein expression of UCP1 in brown adipose tissue by immunofluorescence and densitometry. Quantification of densitometry only showed a significant increase of UCP1 expression after daidzein treatment (A). Representative high-magnification images from the brown adipose tissue immunostained for UCP1 in the four rat groups (STD, STD-daidzein, HFD, HFD-daidzein; B–E). Histograms represent the mean ± SEM (eight animals per group). Two-way ANOVA followed by Bonferroni *post hoc* test: #*P* < 0.05 for daidzein effect. Scale bar is shown in (B).

the main metabolic tissues. Table S3 summarizes the effects induced by the diet and the isoflavone treatment, including the interaction between both factors, in all the parameters analysed in this study.

Our first results showed that the HFD caused weight gain in these animals. Interestingly, acute daidzein dose-

dependently modified feeding, as acute treatment with daidzein (5 mg·kg⁻¹) increased the accumulated HFD intake, whereas a significant intake reduction was observed using 50 mg·kg⁻¹ of daidzein in both STD and HFD, at all the periods analysed in the experiment. This biphasic dose-response effect of daidzein on food intake may be explained as the result of a balance between activated PPARs and ERs, as described for osteogenesis and adipogenesis (Dang and Lowik, 2004). Chronic treatment with daidzein (50 mg·kg⁻¹) reduced body weight, food and calorie intake in both diets. The observed reduction in body weight agrees with other experiments in rodents in which dietary isoflavones significantly decreased body weight and adipose tissue (Michael *et al.*, 2006; Davis *et al.*, 2007; Na *et al.*, 2008; Guo *et al.*, 2009; Kim *et al.*, 2010).

HFDs increase hepatic lipids and adipose tissue, and overweight and obesity can lead to some forms of liver steatosis, mainly due to excessive accumulation of fat in the liver. Here the reversal by daidzein of the increased fat content in the liver produced by the HFD, could indicate a contribution of daidzein in reducing hepatic triglycerides and steatosis. Such effects can induce changes in gene expression profiling, especially of genes involved in adipogenesis or fatty acid β-oxidation. Less hepatic fat accumulation may also improve hepatic insulin resistance.

Consequently, the main objective of this work was to monitor the response of the major genes related to lipid and glucose metabolism, after treatment with daidzein using a STD and a HFD, for the three metabolic tissues: white adipose tissue, liver and skeletal muscle. In adipose tissue, HFD increased gene expression of leptin and the oxidative enzyme ACOX, and decreased that of the lipogenic enzymes ACC and FAS. Comparable effects were found in liver where gene expression of the lipogenic enzymes SCD1 and FAS was decreased and that of ACOX was increased, by HFD. Some of these effects were confirmed after the analysis of SCD1 and FAS protein expression by immunofluorescence. Therefore, it seems that chronic feeding with the HFD inhibited lipogenesis via a reduction in the expression of FAS, ACC and SCD1, and stimulated fat oxidation via ACOX, along with increased leptin, a hormone that regulates food intake and impedes accumulation of fat in non-adipose tissues. Interestingly, the expression of the cannabinoid CB₁ receptors was increased in white adipose tissue which implies a role for the endocannabinoids in these processes; agreeing with previous results (Osei-Hyiaman *et al.*, 2005; Crespillo *et al.*, 2011).

In daidzein-treated, STD-fed rats, we again observed decreased ACC expression in white adipose tissue. Consistent with this, the lipogenic enzymes SCD1 and FAS in liver were also reduced after treatment with the isoflavone and this finding agrees with other work in which FAS mRNA expression was lowered after soy feeding (Nagasawa *et al.*, 2003; Ascencio *et al.*, 2004) and with results from recent similar work (Kim *et al.*, 2010), pointing out that daidzein might alleviate liver steatosis directly, through the transcriptional control of hepatic lipogenesis and fatty acid β-oxidation. The same combination of STD/daidzein decreased the nuclear receptors PPARα and PPARγ in skeletal muscle. Genistein and daidzein bind directly to both PPARα and PPARγ and these effects on the PPARs could be tissue specific. In mouse skeletal muscle, some studies have associated activation of PPARs

with AMP-activated kinase and with improvement in lipid and glucose signalling (Cederroth *et al.*, 2008; Ronis *et al.*, 2009). AMP-activated kinase modulates the activities of transcription factors and co-activators, resulting in either activation or repression of specific genes (Woods *et al.*, 2000). In another study, dietary soy improved insulin sensitivity by increasing glucose uptake in skeletal muscle (Cederroth and Nef, 2009). Whichever pathway is involved, daidzein clearly has an effect on oxidative metabolism in skeletal muscle and our study confirms such effects in animals fed with the STD.

In daidzein-treated, HFD-fed rats, we found changes in some of the genes studied in adipose tissue. The hormones adiponectin and leptin and, particularly, the oxidative enzyme ACOX were reduced. Interestingly, analysing treatment effect, the expression of PPAR α and PPAR γ were also reduced in liver, together with a reduction in SCD1 levels. However, no significant changes were observed in the skeletal muscle in any of the genes studied. Once again, these results point to a possible inhibition of the lipogenic pathways in liver and white adipose tissue.

Clearly, excess of fat consumption after chronic feeding with HFD can influence adipogenesis (Rosen, 2005). Adipogenesis is regulated by the cooperative interaction of various hormones and nuclear receptors, including PPAR γ , modulating the pattern of gene expression and lipid content in fat cells (Harp, 2004; Kota *et al.*, 2005). Recent studies suggested that the effects of isoflavone feeding on insulin sensitivity and lipid homeostasis might also involve, among other factors, altered signalling in the liver through PPAR α and PPAR γ (Ascencio *et al.*, 2004; Shukla *et al.*, 2007).

Furthermore, daidzein can activate ERs as well as PPAR α , and PPAR γ (Dang and Lowik, 2004). A complex balance between activated ERs and PPARs could be an important mechanism in determining the biological effects of isoflavones, such as daidzein and genistein (Dang and Lowik, 2004). In this respect, ERs are expressed in muscle and various other cell types, apart from adipocytes, and the properties of the adipose ER varies with the depot and with different physiological states (Rosen, 2005; Barros *et al.*, 2006).

Several studies have suggested a role for PPAR α in UCP1 expression (Barbera *et al.*, 2001). In addition, PPAR γ acts in brown adipose tissue up-regulating the expression of UCP1, leading to thermogenesis. In terms of the effects of daidzein on thermogenesis, our results would indicate that daidzein treatment in our rats caused an important increase of UCP1 protein expression in brown adipose tissue, suggesting that this isoflavone could regulate uncoupling of ATP production, as a mechanism to deplete energy depots (Xue *et al.*, 2005).

Feeding with soy protein can produce changes in hormone levels (Guo *et al.*, 2009; Ronis *et al.*, 2009) and in our experiments, the levels of adiponectin and leptin in plasma were clearly affected by treatment with daidzein (50 mg·kg⁻¹), with opposite effects on each, results identical to those of Kim *et al.* (2010) measuring leptin and adiponectin in mouse serum. Leptin also mediates specific metabolic effects, including potent depletion of triglycerides from liver and other peripheral tissues. Identification and ranking of genes specifically repressed by leptin showed that SCD1 was at the top of this list and it was specifically repressed during leptin-mediated weight loss (Cohen *et al.*, 2003). However, whether such effects of daidzein were due to changes in the

adipose tissue physiology caused by the weight loss (both adiponectin and leptin are adipocyte-derived hormone playing a pivotal role in regulating food intake and energy expenditure) (Jiang *et al.*, 2005), or due to the hormone-like effects exerted by daidzein after activation of ERs, is still to be determined.

Finally, treatment with daidzein showed a significant reduction in triglycerides and cholesterol levels in plasma. As stated above, HFD and excessive fat accumulation affects the liver, the primary organ regulating metabolism and serum composition as most of the fatty acids and cholesterol from food are processed here before they reach other tissues. Guo *et al.* (2009) found that free fatty acid (FFA) concentration in both plasma and liver was significantly reduced by daidzein indicating that daidzein might influence the elimination of FFAs by mechanisms involving FFA oxidation in the liver and muscle. These results support the use of isoflavones as a nutritional supplement for reducing liver fat in non-alcoholic steatohepatitis. In any case, high-fat feeding can also produce adipocyte hypertrophy and hyperplasia for extra storage (García-Serrano *et al.*, 2011), which might alter the compensatory effects of daidzein, indicating that not only daidzein but also restriction of fat in the diet had to be implemented for this purpose. In addition, the action of isoflavones on PPAR γ can also influence adipocyte differentiation and tissue lipid accumulation, affecting also triglyceride levels in plasma.

In conclusion, our results suggest that daidzein treatment can significantly reduce body weight in rats and also ameliorate the HFD-induced hyperlipidaemia, which can partially explain the anti-steatotic, cholesterol-lowering and insulin-sensitizing effects of soy, confirming previous results with isoflavones (Nagasawa *et al.*, 2003; Shukla *et al.*, 2007; Kim *et al.*, 2010). This general physiological effect shows a complex interaction of many different factors through various possible interrelated pathways, but with a particular role for the inhibition of lipogenesis, involving PPAR γ and the enzyme SCD1. The size of the effect may vary depending on the physiology of the subjects (rat strains, altered leptin/endocannabinoid signalling) as well as the different procedures used (routes of administration) which could be crucial for their physiological functions. Such diversity of actions of isoflavones supports the proposal that their consumption is, overall, beneficial. However, further investigation is needed to evaluate the long-term effects of isoflavones on obesity, type 2 diabetes and its associated disorders, and to assess whether the same mechanisms exist in humans.

Funding

This work is supported by the seventh Framework Programme of European Union (grant number HEALTH-F2-2008-223713, REPROBESITY); Instituto de Salud Carlos III del Ministerio de Ciencia e Innovación (grant numbers PI07/1226, PI07/0953, PI07/0880, SAF2010-19087 and SAF 2010-20521); Instituto de Salud Carlos III del Ministerio de Ciencia e Innovación, UE-ERDF, Red de Trastornos Adictivos (grant number RD06/0001); Instituto de Salud Carlos III del Ministerio de Ciencia e Innovación, UE-ERDF, CIBER OBN; Consejería de Economía, Innovación y Ciencia de la Junta de Andalucía,

UE/ERDF (grant numbers CTS-433, CVI-1038 and P07-CVI-03079); Consejería de salud de la Junta de Andalucía (grant numbers PI0232/2008 and PI0029/2008). F. J. B. S. is recipient of 'Miguel Servet' research contracts from the National System of Health (Instituto de Salud Carlos III, grant number CD07/00283). J. S. is recipient of a 'Sara Borrell' postdoctoral contract from the National System of Health (Instituto de Salud Carlos III, grant number CD08/00203).

Conflicts of interest

There is no conflict of interest reported to this article.

References

- Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1–S254.
- Ascencio C, Torres N, Isoard-Acosta F, Gómez-Pérez FJ, Hernandez-Pando R, Tovar AR (2004). Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr 134: 522–529.
- Barbera MJ, Schluter A, Pedraza N, Iglesias R, Villarroya F, Giralt M (2001). Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J Biol Chem 276: 1486–1493.
- Barros RP, Machado UF, Warner M, Gustafsson JA (2006). Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha. Proc Natl Acad Sci U S A 103: 1605–1608.
- Bathena SJ (2000). Dietary fatty acids and fatty acid metabolism in diabetes. In: Chow CK (ed.). Fatty Acids in Foods and Their Health Implications, 2nd edn. Marcel Dekker: New York, pp. 915–961.
- Bhathena SJ, Velasquez MT (2002). Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 76: 1191–1201.
- Cassidy A, Hooper L (2006). Phytoestrogens and cardiovascular disease. J Br Menopause Soc 12: 49–56.
- Cederroth CR, Nef S (2009). Soy, phytoestrogens and metabolism: a review. Mol Cell Endocrinol 304: 30–42.
- Cederroth CR, Vinciguerra M, Gjinovci A, Kuhne F, Klein M, Cederroth M *et al.* (2008). Dietary phytoestrogens activate AMP-activated protein kinase with improvement in lipid and glucose metabolism. Diabetes 57: 1176–1185.
- Clair RS, Anthony M (2005). Soy, isoflavones and atherosclerosis. Handb Exp Pharmacol 170: 301–323.
- Clarkson TB (2002). Soy, soy phytoestrogens and cardiovascular disease. J Nutr 132: 566S–569S.
- Cohen P, Ntambi JM, Friedman JM (2003). Stearoyl-CoA desaturase-1 and the metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord 3: 271–280.
- Cooke PS, Naaz A (2004). Role of estrogens in adipocyte development and function. Exp Biol Med 229: 1127–1135.
- Crespillo A, Suárez J, Bermúdez-Silva FJ, Rivera P, Vida M, Alonso M *et al.* (2011). Expression of cannabinoid system in muscle: effects of high fat diet and CB1 receptor blockade. Biochem J 433: 175–185.
- Dang Z, Lowik CW (2004). The balance between concurrent activation of ERs and PPARs determines daidzein-induced osteogenesis and adipogenesis. J Bone Miner Res 19: 853–861.
- Davis J, Higginbotham A, O'Connor T, Moustaid-Moussa N, Tebbe A, Kim YC *et al.* (2007). Soy protein and isoflavones influence adiposity and development of metabolic syndrome in obese male ZDF rat. Ann Nutr Metab 51: 42–52.
- Dobrzyn P, Dobrzyn A, Miyazaki M, Cohen P, Asilmz E, Hardie G *et al.* (2004). Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Prot Natl Acad Sci U S A 101: 6409–6414.
- Evans RM, Barish GD, Wang Y (2004). PPARs and the complex journey to obesity. Nat Med 10: 355–361.
- García-Serrano S, Moreno-Santos I, Garrido-Sánchez L, Gutierrez-Repiso C, García-Almeida JM, García-Arnés J *et al.* (2011). Stearoyl-CoA desaturase-1 is associated with insulin resistance in morbidly obese subjects. Mol Med 17: 273–280.
- Godsland IF (2005). Oestrogens and insulin secretion. Diabetologia 48: 2213–2220.
- Guo Y, Wu G, Su X, Yang H, Zhang J (2009). Antiobesity action of a daidzein derivative on male obese mice induced by a high-fat diet. Nutr Res 29: 656–663.
- Harp JB (2004). New insights into inhibitors of adipogenesis. Curr Opin Lipidol 15: 303–307.
- Jiang G, Li Z, Liu F, Ellsworth K, Dallas-Yang Q, Wu M *et al.* (2005). Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin Invest 115: 1030–1038.
- Kim MH, Park JS, Jung JW, Byun KW, Kang KS, Lee YS (2010). Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism. Int J Obes doi:10.1038/ijo.2010.256 [Epub ahead of print].
- Kopelman PG (2000). Obesity as a medical problem. Nature 404: 635–643.
- Kota BP, Huang TH, Roufogalis BD (2005). An overview on biological mechanisms of PPARs. Pharmacol Res 51: 85–94.
- Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT *et al.* (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β . Endocrinology 139: 4252–4263.
- Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS *et al.* (2006). Estrogens protects pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci U S A 103: 9232–9237.
- Liu S, Mauvais-Jarvis F (2010). Estrogenic protection of beta-cell failure in metabolic diseases. Endocrinology 151: 850–864.
- Messina M, Gardner C, Barnes S (2002). Gaining insight into the health effects of soy but a long way still to go: commentary on the fourth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. J Nutr 132: 547S–551S.
- Mezei O, Banz WJ, Steger RW, Peluso MR, Winsten TA, Shay N (2003). Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathway in obese Zucker rats and murine RAW 264.7 cells. J Nutr 133: 1238–1243.
- Mezei O, Li Y, Mullen E, Ross-Viola JS, Shay NF (2006). Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and - independent mechanisms. Physiol Genomics 26: 8–14.

- Michael MR, Wolz E, Davidovich A, Pfannkuch F, Edwards JA, Bausch J (2006). Acute, subchronic and chronic safety studies with genistein in rats. *Food Chem Toxicol* 44: 56–80.
- Mullen E, Brown RM, Osborne TF, Shay NF (2004). Soy isoflavones affect sterol regulatory element binding proteins (SREBPs) and SREBP regulated genes in HepG2 cells. *J Nutr* 34: 2942–2947.
- Na XL, Ezaki J, Sugiyama F, Cui HB, Ishimi Y (2008). Isoflavone regulates lipid metabolism via expression of related genes in OVX rats fed on a high-fat. *Diet* 21: 357–364.
- Nagasawa A, Fukui K, Kojima M, Kishida K, Maeda N, Nagaretani H *et al.* (2003). Divergent effects of soy protein diet on the expression of adipocytokines. *Biochem Biophys Res Commun* 311: 909–914.
- Osei-Hyiaman D, DePetrillo M, Parcher P, Liu J, Radaeva S, Bátkai S *et al.* (2005). Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced-obesity. *J Clin Invest* 115: 1298–1305.
- Piomelli D (2003). The molecular logic of endocannabinoid signaling. *Nat Rev Neurosci* 4: 873–884.
- Ronis MJ, Chen Y, Badeaux J, Badger T (2009). Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR, and SREBP signaling. *J Nutr* 139: 1431–1438.
- Rosen ED (2005). The transcriptional basis of adipocytes development. *Prostaglandins Leukot Essent Fatty Acids* 73: 31–34.
- Severson RK, Nomura AM, Grove JS, Stemmermann GN (1989). A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. *Cancer Res* 49: 1857–1860.
- Shen P, Liu MH, Ng TY, Chan YH, Yong EL (2006). Differential effects of isoflavones, from *Astragalus membranaceus* and *Pueraria thomsonii*, on the activation of PPARalpha, PPARGamma, and adipocyte differentiation in vitro. *J Nutr* 136: 899–905.
- Shin ES, Lee HH, Cho SY, Park HW, Lee SJ, Lee TR (2007). Genistein downregulates SREBP-1 regulated gene expression by inhibiting Site 1 Protease expression in HepG2 cells. *J Nutr* 137: 1127–1131.
- Shukla A, Brandsch C, Bettzieche A, Hirche F, Stangl GI, Eder K (2007). Isoflavone-poor soy protein alters the lipid metabolism of rats by SREBP-mediated down-regulation of hepatic genes. *J Nutr Biochem* 18: 313–321.
- Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S (2007). Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. *Am J Clin Nutr* 85: 1148–1156.
- Tham DM, Gardner CD, Haskell WL (1998). Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. *J Clin Endocrinol Metab* 83: 2223–2235.
- Vedavanam K, Sriyayanta S, O'Reilly J, Raman A, Wiseman H (1999). Antioxidant action and potential antidiabetic properties of an isoflavonoid-containing soyabean phytochemical extract (SPE). *Phytother Res* 13: 601–608.
- Woods A, Azzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P *et al.* (2000). Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. *Mol Cell Biol* 20: 6704–6711.
- Xue B, Coulter A, Rim JS, Koza RA, Kozak LP (2005). Transcriptional synergy and the regulation of Ucp1 during brown adipocyte induction in white fat depots. *Mol Cell Biol* 25: 8311–8322.
- Zhan S, Ho SC (2005). Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. *Am J Clin Nutr* 81: 397–408.
- Zhang C, Ho SC, Lin F, Cheng S, Fu J, Chen Y (2010). Soy product and isoflavone intake and breast cancer risk defined by hormone receptor status. *Cancer Sci* 101: 501–507.
- Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR (2006). Quantitative structure-activity relationship (QSAR) of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insight into the structural determinants favoring a differential subtype binding. *Endocrinology* 147: 4132–4150.
- Zhuo XG, Melby MK, Watanabe S (2004). Soy isoflavone intake lowers serum LDL cholesterol: a meta-analysis of 8 randomized controlled trials in humans. *J Nutr* 134: 2395–2400.

Supporting information

Additional Supporting Information may be found in the online version of this article:

Figure S1 Chemical structure of daidzein (isoflavone), present in *Glycine max* (soybean), 17 β -estradiol (estradiol), Δ^9 -tetrahydrocannabinol (THC), the main cannabinoid receptor agonist present in *Cannabis* preparations, and AM251, a synthetic CB₁ cannabinoid receptor inverse agonist.

Figure S2 Experimental design used for diet-induced obesity and daidzein administration.

Figure S3 Effect of a standard/low-fat diet (STD) and a very high-fat diet (HFD) on accumulated food/caloric intake and body weight gain during 10 weeks. We observed that rats fed with STD accumulated more food intake than rats fed with an HFD (A), in contrast with the accumulated caloric intake (B), and this difference was statistically significant. Body weight gain showed a significant divergence in HFD rats in comparison with STD rats from the eighth week on (C). When body weight gain stabilized over time (at least, for 10 weeks), daidzein was administered, while the diets remained unchanged. Histograms represent the mean $\pm$ SEM (16 animals per diet group). Two-way ANOVA followed by Bonferroni *post test*: * P < 0.05, ** P < 0.01, *** P < 0.001 versus STD rats. Diet effects are summarized in Table S3.

Table S1 Composition of the two diets used to induce obesity in the rats: standard/low-fat diet and high-fat diet

Table S2 Primer sequences used for real-time PCR

Table S3 Summary of the effects produced by diet, treatment and interaction on each parameter analysed¹

Appendix S1 Immunohistochemistry and immunofluorescence.

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.